LSTA · Lisata Therapeutics, Inc.

Lisata Therapeutics disclosed an extension of the tender offer commencement date from April 3, 2026, to April 13, 2026, under the Merger Agreement dated March 6, 2026, with Kuva Labs Inc. (Parent) and its wholly-owned subsidiary Kuva Acquisition Corp. (Purchaser). This delay stems from Parent's efforts to secure alternative financing on more favorable terms, signaling potential challenges in funding the acquisition. The Company remains in active discussions with Parent regarding financing arrangements and launch timing, but emphasizes significant uncertainty, stating there is no assurance the tender offer will proceed. Investors face heightened risks including potential failure to launch, termination of the Merger Agreement, or payment of termination fees. Upon commencement, if it occurs, Parent and Purchaser will file Schedule TO, and Lisata will file Schedule 14D-9 with the SEC, providing detailed terms. This development prolongs uncertainty around the proposed acquisition, originally announced earlier, and underscores financing as a key closing condition that could impact transaction completion.